Table 3.
Univariable survival analysis in patients with clinical stage II or III disease
| RFS | OS | |||
|---|---|---|---|---|
|
|
||||
| Variable | 3-Year RFS (95% CI), % | P | 3-Year OS (95% CI), % | P |
| Sex | 0.58 | 0.83 | ||
| Male | 41 (18-95) | 78 (55-100) | ||
| Female | 45 (26-78) | 69 (49-96) | ||
| Age | 0.54 | 0.16 | ||
| <65 years | 44 (24-82) | 85 (68-100) | ||
| ≥65 years | 42 (20-85) | 56 (32-96) | ||
| Targeted genomic alteration | 0.51 | 0.34 | ||
| EGFR exon 19 deletion | 50 (29-86) | 71 (50-100) | ||
| EGFR L858R mutation | 34 (14-82) | 71 (48-100) | ||
| ALK fusion | NA | 100 (100-100) | ||
| Preoperative treatment type | 0.009 | 0.27 | ||
| Targeted therapy only | 67 (44-100) | 92 (79-100) | ||
| Combination (targeted therapy + chemotherapy) | 27 (12-62) | 60 (40-91) | ||
| ypTNM stage | 0.001 | 0.23 | ||
| 0-1 | 71 (45-100) | 86 (63-100) | ||
| 2-4 | 28 (13-62) | 65 (45-93) | ||
| pT stage | 0.003 | 0.002 | ||
| 0-1 | 65 (43-97) | 94 (83-100) | ||
| 2-4 | 18 (5-61) | 45 (23-89) | ||
| Surgical procedure | 0.141 | 0.30 | ||
| Lobectomy or wedge resection | 44 (27-72) | 73 (56-95) | ||
| Bilobectomy or pneumonectomy | 33 (7-100) | 67 (30-100) | ||
| Radiographic response (RECIST version 1.1) | 0.19 | 0.71 | ||
| Partial response | 61 (32-100) | 83 (58-100) | ||
| Stable disease | 37 (19-72) | 66 (45-96) | ||
| Pathologic response | 0.11 | 0.25 | ||
| Major pathologic response | ||||
| Yes | 100 (100-100) | 100 (100-100) | ||
| No | 32 (16-65) | 58 (38-88) | ||
P values were derived from log-rank tests assessing differences between survival curves by groups. Bold indicates statistically significant values. NA, not achieved; OS, overall survival; RECIST, Response Evaluation Criteria in Solid Tumors; RFS, recurrence-free survival; ypTNM, pathologic tumor, node, metastasis after therapy.